Delivery Order SPE2DB22D1017-SPE2DB24FG1CF

Award Date 7/11/24
Potential Completion Date 7/12/24
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,083.94, is for the delivery of DEXAMETHASONE 20 MG/5 ML VIAL 5ML, a medical product. This is a firm fixed-price Delivery Order contract with an ultimate completion date of June 11, 2024. The contract is not designated with a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery...
This federal contract award, valued at $2,127.55, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of DEXAMETHASONE 10 MG/ML VIALML, a medical product, with a completion date of February 21, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $1,084.49, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award, valued at $1,454.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of dexamethasone 10 mg/ml vials, a specialty medication used in various medical treatments. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,512.17, is for the delivery of dexamethasone 10 mg/ml vials to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with a completion date of February 24, 2025. The contract was not set aside for any specific business type. Amerisourcebergen holds a larger...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of dexamethasone 10 mg/ml vials, a corticosteroid medication, with a ceiling value of $1,971.80 and a completion date of March 4, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $1,358.31 firm-fixed-price delivery order is for the supply of Dexamethasone 0.5 mg/5 ml solution, with a period of performance through February 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $1,059.75, is for the delivery of 4,565,815,786 units of Dexamethasone 20 mg/5 ml vials. This is a firm-fixed price delivery order contract with a completion date of September 17, 2024. The contract is not set-aside. AmerisourceBergen, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government,...
This federal contract award, with ID SPE2DB20D2104|SPE2DB25FLZZV, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,339.99 firm fixed-price delivery order is for the supply of Dexamethasone 0.5 mg/5 ml, an injectable medication, with an ultimate completion date of October 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of dexamethasone 4 mg tablets. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,409.58 and a performance period through November 14, 2024. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB24FG1CF
    Delivery Order

This federal contract award is a delivery order with a ceiling value of $1,652.20 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DEXAMETHASONE 20 MG/5 ML VIAL 5ML medical supplies.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award reviewed is a specific delivery order placed against this DLA IDC, which encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 10:00 AM